Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Avalo Therapeutics (AVTX)
NASDAQ:AVTX
RESEARCH TOOLSreports
Holding AVTX?
Track your performance easily
AVTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.95 - $34.46
Previous Close$8.39
Volume88.97K
Average Volume (3M)83.00K
Market Cap
$87.79M
Enterprise Value$5.93M
Total Cash (Recent Filing)$81.86M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.28
Next Earnings
Mar 27, 2025EPS Estimate
-$1.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-168.23
Shares Outstanding10,393,954
10 Day Avg. Volume239,029
30 Day Avg. Volume82,998
Standard Deviation0.60
R-Squared0.00670
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)4.13
Price to Sales (P/S)106.35
Price to Cash Flow (P/CF)-1.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.23
Enterprise Value/Gross Profit9.27
Enterprise Value/Ebitda0.08
Forecast
1Y Price Target
$33.00Price Target Upside293.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Avalo Therapeutics News
PremiumCompany Announcements
Avalo Therapeutics Appoints New Chief Strategy Officer
Bulls Say, Bears Say
Bulls Say
Financial StabilityManagement expects the company has a cash runway at least into 2027.
Market OpportunityThe market for hidradenitis suppurativa is expected to grow significantly, with AVTX-009 having high odds of showing greater activity than existing treatments.
Product PotentialAVTX-009's superior potency and selectivity for IL-1β, coupled with its better bioavailability and longer half-life compared to competitors, are seen as major advantages.
Bears Say
EarningsAvalo reported a significantly lower earnings per share (EPS) than expected, indicating potential financial struggles.
Financial PerformanceThe company's earnings per share (EPS) came in much worse than anticipated, suggesting potential deeper issues in its financial health.
ProfitabilityA substantial loss per share was reported, far exceeding analyst expectations and raising concerns about the company's profitability.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AVTX FAQ
What was Avalo Therapeutics’s price range in the past 12 months?
Avalo Therapeutics lowest stock price was $3.95 and its highest was $34.46 in the past 12 months.
What is Avalo Therapeutics’s market cap?
Currently, no data Available
When is Avalo Therapeutics’s upcoming earnings report date?
Avalo Therapeutics’s upcoming earnings report date is Mar 27, 2025 which is in 81 days.
How were Avalo Therapeutics’s earnings last quarter?
Avalo Therapeutics released its earnings results on Nov 07, 2024. The company reported -$2.83 earnings per share for the quarter, missing the consensus estimate of -$1.19 by -$1.64.
Is Avalo Therapeutics overvalued?
According to Wall Street analysts Avalo Therapeutics’s price is currently Undervalued.
Does Avalo Therapeutics pay dividends?
Avalo Therapeutics does not currently pay dividends.
What is Avalo Therapeutics’s EPS estimate?
Avalo Therapeutics’s EPS estimate is -$1.42.
How many shares outstanding does Avalo Therapeutics have?
Avalo Therapeutics has 10,463,633 shares outstanding.
What happened to Avalo Therapeutics’s price movement after its last earnings report?
Avalo Therapeutics reported an EPS of -$2.83 in its last earnings report, missing expectations of -$1.19. Following the earnings report the stock price went down -3.657%.
Which hedge fund is a major shareholder of Avalo Therapeutics?
Among the largest hedge funds holding Avalo Therapeutics’s share is RA Capital Management. It holds Avalo Therapeutics’s shares valued at 9M.
---
Avalo Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.00 (293.33% Upside)
$33.00 (293.33% Upside)
Blogger Sentiment
Bullish
AVTX Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth $12.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
6.20%
12-Months-Change
Fundamentals
Return on Equity
-42.52%
Trailing 12-Months
Asset Growth
236.37%
Trailing 12-Months
Company Description
Avalo Therapeutics
Cerecor, Inc. is a clinical stage biopharmaceutical company focuses in medical development. It involves in the discovery, manufacture and commercialization of prescription for neurological and psychiatric disorders. It products include CERC-301, CERC-501, CERC-611, and CERC-406. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher and Solomon H. Snyder on January 31, 2011 and is headquartered in Baltimore, MD.
---
AVTX Stock 12 Month Forecast
Average Price Target
$33.00
▲(293.33% Upside)
Technical Analysis
Eloxx Pharmaceuticals
―
EyePoint Pharmaceuticals
―
Fate Therapeutics
―
Karyopharm Therapeutics
―
Best Analysts Covering AVTX
1 Year
1 Year Success Rate
3/18 ratings generated profit
1 Year Average Return
-39.19%
reiterated a buy rating 2 months ago
Copying Leland Gershell's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -39.19% per trade.
---